Federal Register / Vol. 90, No. 17 / Tuesday, January 28, 2025 / Notices 8299 

1Handbook for Electronic Filing Procedures: 

https://www.usitc.gov/documents/handbook_on_

filing_procedures.pdf. 

2All contract personnel will sign appropriate 

nondisclosure agreements. 

3Electronic Document Information System 

(EDIS): https://edis.usitc.gov. 

any public interest issues raised by the 

amended complaint or § 210.8(b) filing. 

Comments should address whether 

issuance of the relief specifically 

requested by the complainant in this 

investigation would affect the public 

health and welfare in the United States, 

competitive conditions in the United 

States economy, the production of like 

or directly competitive articles in the 

United States, or United States 

consumers. 

In particular, the Commission is 

interested in comments that: 

(i) explain how the articles potentially 

subject to the requested remedial orders 

are used in the United States; 

(ii) identify any public health, safety, 

or welfare concerns in the United States 

relating to the requested remedial 

orders; 

(iii) identify like or directly 

competitive articles that complainant, 

its licensees, or third parties make in the 

United States which could replace the 

subject articles if they were to be 

excluded; 

(iv) indicate whether complainant, 

complainant’s licensees, and/or third 

party suppliers have the capacity to 

replace the volume of articles 

potentially subject to the requested 

exclusion order and/or a cease and 

desist order within a commercially 

reasonable time; and 

(v) explain how the requested 

remedial orders would impact United 

States consumers. 

Written submissions on the public 

interest must be filed no later than by 

close of business, eight calendar days 

after the date of publication of this 

notice in the Federal Register. There 

will be further opportunities for 

comment on the public interest after the 

issuance of any final initial 

determination in this investigation. Any 

written submissions on other issues 

must also be filed by no later than the 

close of business, eight calendar days 

after publication of this notice in the 

Federal Register. Complainant may file 

replies to any written submissions no 

later than three calendar days after the 

date on which any initial submissions 

were due, notwithstanding § 201.14(a) 

of the Commission’s Rules of Practice 

and Procedure. No other submissions 

will be accepted, unless requested by 

the Commission. Any submissions and 

replies filed in response to this Notice 

are limited to five (5) pages in length, 

inclusive of attachments. 

Persons filing written submissions 

must file the original document 

electronically on or before the deadlines 

stated above. Submissions should refer 

to the docket number (‘‘Docket No. 

3801’’) in a prominent place on the 

cover page and/or the first page. (See 

Handbook for Electronic Filing 

Procedures, Electronic Filing 

Procedures 1). Please note the 

Secretary’s Office will accept only 

electronic filings during this time. 

Filings must be made through the 

Commission’s Electronic Document 

Information System (EDIS, https://

edis.usitc.gov.) No in-person paperbased filings or paper copies of any 

electronic filings will be accepted until 

further notice. Persons with questions 

regarding filing should contact the 

Secretary at EDIS3Help@usitc.gov. 

Any person desiring to submit a 

document to the Commission in 

confidence must request confidential 

treatment. All such requests should be 

directed to the Secretary to the 

Commission and must include a full 

statement of the reasons why the 

Commission should grant such 

treatment. See 19 CFR 201.6. Documents 

for which confidential treatment by the 

Commission is properly sought will be 

treated accordingly. All information, 

including confidential business 

information and documents for which 

confidential treatment is properly 

sought, submitted to the Commission for 

purposes of this Investigation may be 

disclosed to and used: (i) by the 

Commission, its employees and Offices, 

and contract personnel (a) for 

developing or maintaining the records 

of this or a related proceeding, or (b) in 

internal investigations, audits, reviews, 

and evaluations relating to the 

programs, personnel, and operations of 

the Commission including under 5 

U.S.C. appendix 3; or (ii) by U.S. 

Government employees and contract 

personnel 2, solely for cybersecurity 

purposes. All nonconfidential written 

submissions will be available for public 

inspection at the Office of the Secretary 

and on EDIS 3. 

This action is taken under the 

authority of section 337 of the Tariff Act 

of 1930, as amended (19 U.S.C. 1337), 

and of §§ 201.10 and 210.8(c) of the 

Commission’s Rules of Practice and 

Procedure (19 CFR 201.10, 210.8(c)). 

By order of the Commission. 

Issued: January 23, 2025. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2025–01815 Filed 1–27–25; 8:45 am] 

BILLING CODE 7020–02–P 

INTERNATIONAL TRADE 

COMMISSION 

[Investigation No. 337–TA–1377] 

Certain Products Containing 

Tirzepatide and Products Purporting 

To Contain Tirzepatide; Notice of a 

Commission Determination Not To 

Review an Initial Determination Finding 

Respondents in Violation of Section 

337; Request for Written Submissions 

on Remedy, the Public Interest, and 

Bonding 

AGENCY: U.S. International Trade 

Commission. 

ACTION: Notice. 

SUMMARY: Notice is hereby given that 

the U.S. International Trade 

Commission (‘‘Commission’’) has 

determined not to review an initial 

determination (‘‘ID’’) (Order No. 26) of 

the presiding administrative law judge 

(‘‘ALJ’’), partially granting a motion for 

summary determination on violation of 

section 337. The Commission requests 

written submissions from the parties, 

interested government agencies, and 

other interested persons on the issues of 

remedy, the public interest, and 

bonding, under the schedule set forth 

below. 

FOR FURTHER INFORMATION CONTACT: 

Ronald A. Traud, Esq., Office of the 

General Counsel, U.S. International 

Trade Commission, 500 E Street SW, 

Washington, DC 20436, telephone (202) 

205–3427. Copies of non-confidential 

documents filed in connection with this 

investigation may be viewed on the 

Commission’s electronic docket (EDIS) 

at https://edis.usitc.gov. For help 

accessing EDIS, please email 

EDIS3Help@usitc.gov. General 

information concerning the Commission 

may also be obtained by accessing its 

internet server at https://www.usitc.gov. 

Hearing-impaired persons are advised 

that information on this matter can be 

obtained by contacting the 

Commission’s TDD terminal on (202) 

205–1810. 

SUPPLEMENTARY INFORMATION: The 

Commission instituted this investigation 

on November 27, 2023, based upon a 

complaint filed on behalf of Eli Lilly 

and Company of Indianapolis, Indiana 

(‘‘Lilly’’). 88 FR 82914, 82914–15 (Nov. 

27, 2023). The complaint, as 

supplemented, alleges violations of 

section 337 based upon the importation 

into the United States, the sale for 

importation, and the sale within the 

United States after importation of 

certain products containing tirzepatide 

or purporting to contain tirzepatide by 

reason of false designation of source and 


ddrumheller on DSK120RN23PROD with NOTICES1
8300 Federal Register / Vol. 90, No. 17 / Tuesday, January 28, 2025 / Notices 

false and misleading advertising, the 

threat or effect of which is to destroy or 

substantially injure an industry in the 

United States, and by reason of 

infringement of U.S. Trademark No. 

6,809,369. Id. The complaint also 

alleges that a domestic industry exists 

pursuant to subsection (a)(2) of section 

337. Id. The Commission’s notice of 

investigation named as respondents: (1) 

Arctic Peptides LLC of Akeny, Iowa 

(‘‘Arctic Peptides’’); (2) Audrey Beauty 

Co. of Hong Kong, China (‘‘Audrey 

Beauty’’); (3) Biolabshop Limited of 

Lancaster, United Kingdom 

(‘‘Biolabshop’’); (4) Mew Mews 

Company Limited of Hong Kong, China 

(‘‘Mew Mews’’); (5) Strate Labs LLC of 

Spring, Texas (‘‘Strate Labs’’); (6) 

Steroide Kaufen of Bialystok, Poland 

(‘‘Steroide Kaufen’’); (7) Super Human 

Store of Barcelona, Spain (‘‘SHS’’); (8) 

Supopeptide of Cedar Grove, New Jersey 

(‘‘Supopeptide’’); (9) Triggered 

Supplements LLC (d/b/a The Triggered 

Brand) of Clearwater, Florida 

(‘‘Triggered Brand’’); (10) Unewlife of 

Cedar Grove, New Jersey (‘‘Unewlife’’); 

and (11) Xiamen Austronext Trading 

Co., Ltd. (d/b/a AustroPeptide) of 

Fujian, China (‘‘AustroPeptide’’). Id. at 

82915. The Office of Unfair Import 

Investigations (‘‘OUII’’) is also named as 

a party in this investigation. Id. 

On March 21, 2024, the investigation 

terminated in part, based on withdrawal 

of the related allegations in the 

complaint, as to respondents Unewlife, 

Supopeptide, and Steroide Kaufen. 

Order No. 8 (Mar. 7, 2024), unreviewed 

by Comm’n Notice (Mar. 21, 2024). 

On May 15, 2024, the Commission 

found Arctic Peptides, Audrey Beauty, 

Biolabshop, Mew Mews, Strate Labs, 

SHS, Triggered Brand, and 

AustroPeptide in default. Order No. 13 

(Apr. 22, 2024), unreviewed by Comm’n 

Notice (May 15, 2024). 

On May 21, 2024, the complaint was 

amended to add as respondents 

Fibonacci Sequence LLC (d/b/a GenX 

Peptides) of Houston, Texas (‘‘GenX 

Peptides’’); and Paradigm Peptides of 

Michigan City, Indiana (‘‘Paradigm 

Peptides’’). Order No. 12 (Apr. 22, 

2024), unreviewed by Comm’n Notice 

(May 21, 2024), available at 89 FR 

46159, 46159–60 (May 28, 2024). 

On June 13, 2024, the complaint was 

further amended to add as a respondent 

Total Compounding Pharmaceuticals of 

Australia (‘‘Total Compounding’’). 

Order No. 16 (May 8, 2024), unreviewed 

by Comm’n Notice (June 13, 2024), 

available at 89 FR 5149, 51549–50 (June 

18, 2024). 

On October 16, 2024, the Commission 

found GenX Peptides in default. Order 

No. 23 (Aug. 27, 2024), unreviewed by 

Comm’n Notice (Oct. 16, 2024). 

On July 12, 2024, Lilly moved for 

summary determination on violation 

based on allegations of trademark 

infringement, false designation of origin, 

and/or false advertising against (1) 

Arctic Peptides, (2) Audrey Beauty, (3) 

Biolabshop, (4) Mew Mews, (5) Strate 

Labs, (6) SHS, (7) Triggered Brand, (8) 

AustroPeptide, (9) GenX Peptides, (10) 

Paradigm Peptides, and (11) Total 

Compounding. On December 6, 2024, 

the ALJ issued the subject ID, which 

partially granted the motion. Order No. 

26 (Dec. 6, 2024). The ID granted Lilly’s 

motion regarding trademark 

infringement as to respondents Audrey 

Beauty, Mew Mews, SHS, and Triggered 

Brand, but denied the motion as to 

GenX Peptides, Total Compounding, 

Paradigm Peptides, and Strate Labs. E.g., 

ID at 134 (including n.61). The ID 

granted Lilly’s motion regarding false 

designation of origin as to respondents 

Audrey Beauty, Mew Mews, SHS, 

Triggered Brand, and Strate Labs, but 

denied the motion as to GenX Peptides, 

Total Compounding, Paradigm Peptides, 

and Biolabshop. E.g., id. (including n. 

62). And the ID granted Lilly’s motion 

as to false advertising as to respondents 

SHS, AustroPeptide, and Arctic 

Peptides. E.g., id. The ID additionally 

found that Lilly is entitled to summary 

determination as to the domestic 

industry requirement. E.g., id. No 

petitions for review of the ID were filed. 

The subject ID included the ALJ’s 

Preliminary Recommended 

Determination on Remedy and Bond 

(‘‘RD’’), should a violation be found. 

The RD recommended: (1) a general 

exclusion order directed to certain 

products containing tirzepatide and 

products purporting to contain 

tirzepatide imported, sold for 

importation, and/or sold after 

importation for the asserted trademark 

infringement and false designation of 

origin allegations; (2) in the alternative 

to a general exclusion order for the 

asserted trademark infringement and 

false designation of origin allegations, 

limited exclusion orders directed to 

Audrey Beauty, Mew Mews, SHS, 

Triggered Brand, Strate Labs, and 

AustroPeptide; (3) limited exclusion 

orders directed to SHS and 

AustroPeptide for the false advertising 

allegations; and (4) in addition to either 

a general exclusion order or limited 

exclusion orders, cease and desist 

orders directed to Arctic Peptides, 

Triggered Brand, and Strate Labs. The 

Commission notes that only the portions 

of Order No. 26 that correspond to a 

grant of a summary determination of 

violation for a particular respondent and 

claim are ripe for review at this time. 

Having reviewed the record of the 

investigation, including the ID and the 

parties’ submissions to the ALJ, the 

Commission has determined not to 

review the ID. 

In connection with the final 

disposition of this investigation, the 

statute authorizes issuance of, inter alia, 

(1) an exclusion order that could result 

in the exclusion of the subject articles 

from entry into the United States; and/ 

or (2) cease and desist orders that could 

result in the respondents being required 

to cease and desist from engaging in 

unfair acts in the importation and sale 

of such articles. Accordingly, the 

Commission is interested in receiving 

written submissions that address the 

form of remedy, if any, that should be 

ordered. If a party seeks exclusion of an 

article from entry into the United States 

for purposes other than entry for 

consumption, the party should so 

indicate and provide information 

establishing that activities involving 

other types of entry either are adversely 

affecting it or likely to do so. For 

background, see Certain Devices for 

Connecting Computers via Telephone 

Lines, Inv. No. 337–TA–360, USITC 

Pub. No. 2843, Comm’n Op. at 7–10 

(Dec. 1994). 

The statute requires the Commission 

to consider the effects of that remedy 

upon the public interest. The public 

interest factors the Commission will 

consider include the effect that an 

exclusion order and cease and desist 

orders would have on: (1) the public 

health and welfare, (2) competitive 

conditions in the U.S. economy, (3) U.S. 

production of articles that are like or 

directly competitive with those that are 

subject to investigation, and (4) U.S. 

consumers. The Commission is 

therefore interested in receiving written 

submissions that address the 

aforementioned public interest factors 

in the context of this investigation. 

If the Commission orders some form 

of remedy, the U.S. Trade 

Representative, as delegated by the 

President, has 60 days to approve, 

disapprove, or take no action on the 

Commission’s determination. See 

Presidential Memorandum of July 21, 

2005, 70 FR 43251 (July 26, 2005). 

During this period, the subject articles 

would be entitled to enter the United 

States under bond, in an amount 

determined by the Commission and 

prescribed by the Secretary of the 

Treasury. The Commission is therefore 

interested in receiving submissions 

concerning the amount of the bond that 

should be imposed if a remedy is 

ordered. 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 90, No. 17 / Tuesday, January 28, 2025 / Notices 8301 

1A record of the Commissioners’ votes, the 

Commission’s statement on adequacy, and any 

individual Commissioner’s statements will be 

available from the Office of the Secretary and at the 

Commission’s website. 

2Commissioner Johanson voted to conduct full 

reviews. 

Written Submissions: Parties to the 

investigation, interested government 

agencies, and any other interested 

parties are encouraged to file written 

submissions on the issues of remedy, 

the public interest, and bonding. Such 

submissions should address the 

recommended determination by the ALJ 

on remedy and bonding. 

In its initial submission, Complainant 

is also requested to identify the remedy 

sought and Complainant and OUII are 

requested to submit proposed remedial 

orders for the Commission’s 

consideration. Complainant is further to 

provide the HTSUS subheadings under 

which the accused products are 

imported, and to supply the 

identification information for all known 

importers of the products at issue in this 

investigation. The initial written 

submissions and proposed remedial 

orders must be filed no later than close 

of business on February 5, 2025. Reply 

submissions must be filed no later than 

the close of business on February 12, 

2025. No further submissions on these 

issues will be permitted unless 

otherwise ordered by the Commission. 

No further submissions on any of these 

issues will be permitted unless 

otherwise ordered by the Commission. 

Persons filing written submissions 

must file the original document 

electronically on or before the deadlines 

stated above. The Commission’s paper 

filing requirements in 19 CFR 210.4(f) 

are currently waived. 85 FR 15798 (Mar. 

19, 2020). Submissions should refer to 

the investigation number (Inv. No. 337– 

TA–1377) in a prominent place on the 

cover page and/or the first page. (See 

Handbook for Electronic Filing 

Procedures, https://www.usitc.gov/ 

documents/handbook_on_filing_

procedures.pdf). Persons with questions 

regarding filing should contact the 

Secretary, (202) 205–2000. 

Any person desiring to submit a 

document to the Commission in 

confidence must request confidential 

treatment by marking each document 

with a header indicating that the 

document contains confidential 

information. This marking will be 

deemed to satisfy the request procedure 

set forth in Rules 201.6(b) and 

210.5(e)(2) (19 CFR 201.6(b) & 

210.5(e)(2)). Documents for which 

confidential treatment by the 

Commission is properly sought will be 

treated accordingly. Any non-party 

wishing to submit comments containing 

confidential information must serve 

those comments on the parties to the 

investigation pursuant to the applicable 

Administrative Protective Order. A 

redacted non-confidential version of the 

document must also be filed with the 

Commission and served on any parties 

to the investigation within two business 

days of any confidential filing. All 

information, including confidential 

business information and documents for 

which confidential treatment is properly 

sought, submitted to the Commission for 

purposes of this investigation may be 

disclosed to and used: (i) by the 

Commission, its employees and Offices, 

and contract personnel (a) for 

developing or maintaining the records 

of this or a related proceeding, or (b) in 

internal investigations, audits, reviews, 

and evaluations relating to the 

programs, personnel, and operations of 

the Commission including under 5 

U.S.C. appendix 3; or (ii) by U.S. 

Government employees and contract 

personnel, solely for cybersecurity 

purposes. All contract personnel will 

sign appropriate nondisclosure 

agreements. All nonconfidential written 

submissions will be available for public 

inspection on EDIS. 

The Commission vote for this 

determination took place on January 22, 

2025. 

The authority for the Commission’s 

determination is contained in section 

337 of the Tariff Act of 1930, as 

amended (19 U.S.C. 1337), and in part 

210 of the Commission’s Rules of 

Practice and Procedure (19 CFR part 

210). 

By order of the Commission. 

Issued: January 22, 2025. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2025–01785 Filed 1–27–25; 8:45 am] 

BILLING CODE 7020–02–P 

INTERNATIONAL TRADE 

COMMISSION 

[Investigation Nos. 701–TA–455 and 731– 

TA–1149 (Third Review)] 

Circular Welded Carbon Quality Steel 

Line Pipe From China; Scheduling of 

Expedited Five-Year Reviews 

AGENCY: United States International 

Trade Commission. 

ACTION: Notice. 

SUMMARY: The Commission hereby gives 

notice of the scheduling of expedited 

reviews pursuant to the Tariff Act of 

1930 (‘‘the Act’’) to determine whether 

revocation of the antidumping duty and 

countervailing duty orders on circular 

welded carbon quality steel line pipe 

from China would be likely to lead to 

continuation or recurrence of material 

injury within a reasonably foreseeable 

time. 

DATES: December 9, 2024. 

FOR FURTHER INFORMATION CONTACT: Juan 

Carlos Pena Flores—(202) 205–3169), 

Office of Investigations, U.S. 

International Trade Commission, 500 E 

Street SW, Washington, DC 20436. 

Hearing-impaired persons can obtain 

information on this matter by contacting 

the Commission’s TDD terminal on 202– 

205–1810. Persons with mobility 

impairments who will need special 

assistance in gaining access to the 

Commission should contact the Office 

of the Secretary at 202–205–2000. 

General information concerning the 

Commission may also be obtained by 

accessing its internet server (https://

www.usitc.gov). The public record for 

this proceeding may be viewed on the 

Commission’s electronic docket (EDIS) 

at https://edis.usitc.gov. 

SUPPLEMENTARY INFORMATION: 

Background.—On December 9, 2024, 

the Commission determined that the 

domestic interested party group 

response to its notice of institution (89 

FR 71419, September 3, 2024) of the 

subject five-year reviews was adequate 

and that the respondent interested party 

group response was inadequate. The 

Commission did not find any other 

circumstances that would warrant 

conducting full reviews.1 Accordingly, 

the Commission determined that it 

would conduct expedited reviews 

pursuant to section 751(c)(3) of the Act 

(19 U.S.C. 1675(c)(3)).2

For further information concerning 

the conduct of these reviews and rules 

of general application, consult the 

Commission’s Rules of Practice and 

Procedure, part 201, subparts A and B 

(19 CFR part 201), and part 207, 

subparts A, D, E, and F (19 CFR part 

207). 

Staff report.—A staff report 

containing information concerning the 

subject matter of the reviews has been 

placed in the nonpublic record, and will 

be made available to persons on the 

Administrative Protective Order service 

list for these reviews on February 12, 

2025. A public version will be issued 

thereafter, pursuant to § 207.62(d)(4) of 

the Commission’s rules. 

Written submissions.—As provided in 

§ 207.62(d) of the Commission’s rules, 

interested parties that are parties to the 

reviews and that have provided 

individually adequate responses to the 


ddrumheller on DSK120RN23PROD with NOTICES1